Clinical trials: Lymphatic System Neoplasm
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Polycythemia Vera
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
This is an open-label, single-arm study of idasanutlin monotherapy in participants with hydroxyurea (HU)-resistant/intolerant Polycythemia vera (PV). The study will include two phases: initial phase and expansion phase.
- Trial name
- NCT03287245
- Testing
- Idasanutlin
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00816595
- Testing
- bevacizumab, pegfilgrastim, rituximab
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
This pilot clinical trial studies the side effects of lenalidomide and ipilimumab after stem cell transplant in treating patients with hematologic or lymphoid malignancies.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT01919619
- Testing
- Ipilimumab, Lenalidomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Waldenstrom's Macroglobulinemia
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02604511
- Testing
- Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for patients with iron overload who are receiving a stem cell transplant.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00658411
- Testing
- deferoxamine
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone…
- Trial name
- NCT00622336
- Testing
- CC-5013, Lenalidomide
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 330 people
- Sponsor
- Celgene
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL).
- Conditions
- Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
- Trial name
- NCT04938232
- Testing
- Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
T-cell Depleted Alternative Donor Transplantation
The primary purpose is to determine the ability of CD34+ selection and T cell depletion using the CliniMACS® device to prevent severe acute graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from an…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00968864
- Testing
- CliniMACS® (T cell depletion)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Wake Forest University Health Sciences
Hairy Cell Leukemia
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia
BL22 is a type of protein that scientists have created to interact with certain cancer cells. Experiments have shown that BL22 can bind with cancer cells that have a particular kind of protein (called CD22 ) on their surface, and…
- Trial name
- NCT00924040
- Testing
- BL22 (CAT-3888)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma,Non-Hodgkin
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have…
- Trial name
- CHRONOS-3 (NCT02367040)
- Testing
- Copanlisib (Aliqopa, BAY80-6946), Rituximab
- Where
- 187 sites in United States, Argentina and 35 more
- Volunteers
- 458 people
- Sponsor
- Bayer
Mantle-Cell Lymphoma
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
- Trial name
- SYMPATICO (NCT03112174)
- Testing
- Ibrutinib, Venetoclax
- Where
- 120 sites in United States, Australia and 15 more
- Volunteers
- 366 people
- Sponsor
- Pharmacyclics LLC.
Multiple Myeloma
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
- Trial name
- CHAMPION 2 (NCT01980589)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Diffuse Large B Cell Lymphoma
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
This is a phase I/II open label, multi-center study of azacytidine in combination with standard RCHOP therapy in patients with DLBCL.
- Trial name
- NCT01004991
- Testing
- rituximab, cyclophosphamide, vincristine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating…
- Trial name
- NCT00091260
- Testing
- dexamethasone, lenalidomide
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Vaishali Sanchorawala
Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Primary Objective: To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL.
- Trial name
- NCT00794820
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.